The financial performance, as represented by common-size income statements, exhibits notable fluctuations over the observed period. Revenue composition shifts are apparent, alongside significant variations in profitability metrics. A detailed examination reveals evolving trends in cost structure and expense management.
Revenue Composition
Product revenues consistently represent the largest portion of total revenues, ranging from approximately 81.58% to 87.75% over the analyzed timeframe. Alliance revenues demonstrate a fluctuating contribution, peaking at 15.56% and reaching a low of 10.73%. Royalty revenues remain a smaller, but growing, component, increasing from 1.10% to 2.91% by the end of the period. These shifts suggest a dynamic revenue mix, with increasing reliance on alliance and royalty income relative to core product sales.
Gross Profit
Gross profit as a percentage of revenue demonstrates considerable volatility. It begins at 71.36% in April 2021, declines to a low of 58.68% in October 2021, and then rises to a high of 77.29% in March 2024 before decreasing again to 69.97% in December 2025. This suggests fluctuations in production costs or pricing strategies. The significant drop in gross profit margin in late 2021 and early 2022 warrants further investigation.
Operating Income
Operating income exhibits even more pronounced swings than gross profit. It starts at 32.30% in April 2021, reaches a peak of 44.05% in July 2022, then experiences a substantial decline, falling to a loss of -23.50% in September 2023. A partial recovery is observed in subsequent periods, reaching 16.36% in December 2025. This volatility is likely influenced by changes in both gross profit and operating expenses.
Operating Expenses
Selling, informational, and administrative expenses generally remain between 10.10% and 31.40% of revenues, with a notable increase in July 2022 (26.89%) and September 2023 (31.30%). Research and development expenses fluctuate between 8.97% and 20.36%, with a similar peak in July 2022 (20.36%). Acquired in-process research and development expenses are generally low, but experience a significant spike to 8.35% in September 2025. Amortization of intangible assets remains relatively stable, between 2.96% and 9.84%. Restructuring charges and acquisition-related costs are generally minimal, except for a substantial impact in September 2023 (-17.61%). The combined effect of these expenses significantly impacts operating income.
Net Income
Net income attributable to Pfizer Inc. common shareholders mirrors the trends observed in operating income, fluctuating considerably. It begins at 33.60% in April 2021, declines to a loss of -9.38% in December 2025. The impact of discontinued operations is minimal, with only small adjustments to net income. The significant decline in net income in the latter part of the period is a key observation.
Tax Rate
The effective tax rate, as indicated by the (provision) benefit for taxes on income (loss) as a percentage of revenue, varies considerably. It ranges from -5.94% to 7.14%, suggesting the presence of tax benefits or losses in certain periods. A significant benefit is observed in September 2023 (7.14%), potentially mitigating some of the operating losses experienced during that period.
Overall, the financial performance demonstrates a period of significant change and volatility. While revenue composition remains relatively stable, profitability metrics are subject to substantial fluctuations, driven by variations in cost of sales, operating expenses, and tax provisions. The period from September 2023 to December 2025 appears particularly challenging, with significant declines in operating and net income.
